J Cancer 2020; 11(22):6695-6699. doi:10.7150/jca.49269 This issue

Research Paper

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients

Wei Zuo1*, Yan He2*, Wei Li3, Hao Wu3, Zhengyi Zhao4, Yuzi Zhang4, Shiqing Chen4, Yongmei Yin3✉

1. Department of Respiratory, The First Affiliated Hospital of Nanchang University, Jiangxi, China
2. The Second Shenzhen People's hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
3. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
4. The Medical Department, 3D Medicines, Inc. Shanghai, China
*Dr. Wei Zuo and Yan He contributed equally to this work and serve as co-first authors.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Zuo W, He Y, Li W, Wu H, Zhao Z, Zhang Y, Chen S, Yin Y. Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients. J Cancer 2020; 11(22):6695-6699. doi:10.7150/jca.49269. Available from https://www.jcancer.org/v11p6695.htm

File import instruction

Abstract

Purpose: The aberrant of fibroblast growth factors and their receptors (FGF/FGFR) is an emerging target in the treatment of solid tumors. This study aimed to explore the landscape of FGF/FGFR alterations in a large cohort of cancer patients.

Material and Methods: The formalin-fixed paraffin-embedded specimens of cancer patients who have underwent next-generation sequencing (NGS) from 2017 to 2019 in 3DMed Clinical Laboratory Inc. were included in this study.

Findings: Of 12,372 Chinese cancer patients with more than 20 tumor types (60% male, median age, 58.0 [IQR, 49.0-66.0]), genomic alterations in FGF, FGFR, and both were observed in 895 (7.2%), 862 (7.0%), and 186 (1.5%) patients, respectively. The highest prevalence of FGF/FGFR mutations fell in esophagus cancer (61.6%, 98/159) and urinary tract cancer (52.7%, 145/275). The most common pathway-level mutations were FGFR single nucleotide variants (635, 5.1%) and FGF amplifications (628, 5.1%). The microsatellite instability status was negatively associated with amplifications (p=0.0017).

Conclusion: FGF/FGFR alterations were widely occurred in cancer patients, and the mutational landscape may contribute to the further study design and development of FGF/FGFR inhibitors.

Keywords: Fibroblast growth factor receptor, Next-generation sequencing, Solid tumor